Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the
prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the …

A combination of advances spanning from isolation to delivery of potent HIV-specific
antibodies has begun to revolutionize understandings of antibody-mediated antiviral activity …

Monoclonal antibodies are routinely used as therapeutics in a number of disease settings
and have thus also been explored as potential treatment for human immunodeficiency virus …

Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency
syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is …

Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …

Efforts to cure human immunodeficiency virus (HIV) infection are obstructed by reservoirs of
latently infected CD4+ T cells that can reestablish viremia. HIV-specific broadly neutralizing …

Combination antiretroviral therapy (cART) is effective but not curative, and no successful
vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly …

Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …

Current antiretroviral drug therapies do not cure HIV-1 because they do not eliminate a pool
of long-lived cells harboring immunologically silent but replication-competent proviruses …

Multiple roles for HIV broadly neutralizing antibodies | Science Translational Medicine news
careers commentary Journals Science Science brought to you byGoogle Indexer Log in science …